A battle between hospitals and pharmaceutical companies is brewing over the 340B program; Uber and other companies relying on independent contractors lead the push to get people to enroll in Obamacare plans; the government intends to crack down harder on fentanyl-related substances.
Hospitals and the trade organization representing pharmaceutical companies are facing off over the 340B program. According to Politico, drug companies want fewer drugs sold through the program, while hospitals want to expand it. The companies allege that the discounts through the program have led to hospitals buying up more doctor’s offices, which increases healthcare costs. Hospitals argue that the program is needed to provide drugs to vulnerable populations. Both sides are spending money to retain lobbying firms to advocate their position on 340B.
The Trump administration may have cut funding to market the Affordable Care Act (ACA)’s open enrollment, but Uber and other technology companies in Silicon Valley are filling the void. Uber will hold events for its drivers to offer assistance to sign up for ACA insurance plans, reported The New York Times. The company will partner on enrollment efforts with Stride Health, which is also working with other companies that rely on independent contractors, like Etsy Inc, DoorDash Inc, and Postmates Inc.The Drug Enforcement Administration (DEA) is planning to temporarily schedule fentanyl-related substances on an emergency basis, which would make it easier to prosecute traffickers of synthetic opioids. The Hill reported that people trafficking substances like fentanyl will be charged the same as people trafficking fentanyl. A temporary scheduling can last up to 2 years and will go into effect 30 days after the DEA publishes notice.
Mental Health Diagnoses, Care Challenges Rise Among US Youth, Report Finds
April 26th 2024While behavioral health care utilization has been rising, the treatment landscape has been falling. New findings show that 20% of youths did not receive any form of treatment within 3 months of their initial behavioral health diagnosis.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More